Indivior PLC (LON:INDV – Get Free Report) was down 15.7% during mid-day trading on Thursday . The stock traded as low as GBX 548.71 ($6.93) and last traded at GBX 732 ($9.25). Approximately 1,888,371 shares were traded during mid-day trading, an increase of 166% from the average daily volume of 709,477 shares. The stock had previously closed at GBX 868 ($10.97).
Wall Street Analysts Forecast Growth
Separately, Jefferies Financial Group reiterated a “buy” rating and issued a GBX 1,800 ($22.74) target price on shares of Indivior in a research note on Tuesday, December 17th.
Check Out Our Latest Stock Report on Indivior
Indivior Stock Performance
Indivior Company Profile
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Stories
- Five stocks we like better than Indivior
- What is diluted earnings per share (Diluted EPS)?
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- What does consumer price index measure?
- DuPont’s Electronics Spinoff: The Start of Something Big
- How to Evaluate a Stock Before Buying
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.